865233-36-9

Basic information

• Product Name: (3S)-3-(4-Hydroxy-phenyl)-hex-4-ynoic acid methyl ester
• Synonyms: (3S)-3-(4-Hydroxy-phenyl)-hex-4-ynoic acid methyl ester;(S)-methyl 3-(4-hydroxyphenyl)hex-4-ynoate
• CAS NO: 865233-36-9
• Molecular Formula: C₁₃H₁₄O₃
• Molecular Weight: 218.24846
• EINECS: -0
• Mol File: 865233-36-9.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (3S)-3-(4-Hydroxy-phenyl)-hex-4-ynoic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (3S)-3-(4-Hydroxy-phenyl)-hex-4-ynoic acid methyl ester(865233-36-9)
• EPA Substance Registry System: (3S)-3-(4-Hydroxy-phenyl)-hex-4-ynoic acid methyl ester(865233-36-9)

Safety Data

• Hazardous Substances Data: 865233-36-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(3S)-3-(4-hydroxy-phenyl)-hex-4-ynoic acid methyl ester is used as a reagent in the synthesis of GPR40 agonists, which are potential antidiabetic agents. These agonists have the ability to stimulate the GPR40 receptor, a G-protein coupled receptor expressed in pancreatic β-cells, leading to increased insulin secretion and improved glucose tolerance in diabetic patients. The development of such agents can provide a novel approach to managing type 2 diabetes and its associated complications.

Upstream product

• 74-88-4 methyl iodide 
• 865233-35-8 (3S)-3-(4-hydroxy-phenyl)-hex-4-ynoic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 67-56-1 methanol 
• 1146212-20-5 acetic acid 4-(2,2-dimethyl-4,6-dioxo[1,3]dioxan-5-ylidenemethyl)-phenyl ester 
• 865233-33-6 (+/-)-5-[1-(4-hydroxy-phenyl)-but-2-ynyl]-2,2-dimethyl-[1,3]dioxane-4,6-dione 
• 865233-34-7 4-hydroxy-β-1-propyn-1-ylbenzenepropanoic acid 
• 1092773-21-1 (3S)-3-(4-hydroxyphenyl)hex-4-ynoic acid (1S,2R)-1-amino-2,3-dihydro-1H-inden-2-ol salt 
• 865233-82-5 2,2-Dimethyl-5-[4-(tetrahydro-pyran-2-yloxy)-benzylidene]-[1,3]dioxane-4,6-dione 
• 1291087-13-2 C₁₈H₁₈O₆ 
• 17474-27-0 5-(4-hydroxy-benzylidene)-2,2-dimethyl-[1,3]dioxane-4,6-dione 
• 123-08-0 4-hydroxy-benzaldehyde 
• 865234-02-2 methyl 3-(4-hydroxyphenyl-1-propynyl)propanoate 

Downstream Products

• 865233-37-0 (3S)-3-[4-(4'-trifluoromethyl-biphenyl-3-ylmethoxy)-phenyl]-hex-4-ynoic acid methyl ester 
• 865231-46-5 [3H]-AMG 837 
• 865233-35-8 (3S)-3-(4-hydroxy-phenyl)-hex-4-ynoic acid 
• 1073545-20-6 methyl (3S)-3-(4-(((6-(1,1-dimethylethyl)-2'-fluoro-5'-(methyloxy)-1,1'-biphenyl-3-yl)methyl)oxy)phenyl)-4-hexynoate 
• 1073545-27-3 methyl (3S)-3-(4-hydroxyphenyl)hexanoate 
• 929713-37-1 C₂₂H₂₂O₃ 
• 929713-35-9 (3S)-methyl 3-(4-(5-bromo-2,3-dihydro-1H-inden-1-yloxy)phenyl)hex-4-ynoate 

Relevant articles and documents

3-PHENYL-4-HEXYNOIC ACID DERIVATIVES AS GPR40 AGONISTS

A compound of the formula (I)wherein R represents a straight or branched, primary or secondary acyclic hydrocarbyl C3–C15 group, which can be saturated or unsaturated, or a straight or branched, primary or secondary acyclic hydrocarbyl C3–C15 group, which can be saturated or unsaturated and wherein one or more of hydrogen atoms is replaced with fluorine atom; X represents hydrogen atom or halogen atom,and* denotes chiral center, and salts thereof. The compound is useful for the treatment of diseases mediated by GPR40, in particular type II diabetes. (I)

NOVEL PHENYL PROPIONIC ACID DERIVATIVES AND USES THEREOF

The present invention relates to the compounds according to Formula (I), the racemates, enantiomers, diastereomers thereof or pharmaceutical acceptable salts thereof, or pharmaceutical compositions comprising these, for the treatment or prevention of meta

ANTIDIABETIC BICYCLIC COMPOUNDS

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

AMG 837: A potent, orally bioavailable GPR40 agonist

The discovery that certain long chain fatty acids potentiate glucose stimulated insulin secretion through the previously orphan receptor GPR40 sparked interest in GPR40 agonists as potential antidiabetic agents. Optimization of a series of β-substituted p

Development of a scalable synthesis of a GPR40 receptor agonist

Early process development and salt selection for AMG 837, a novel GPR40 receptor agonist, is described. The synthetic route to AMG 837 involved the convergent synthesis and coupling of two key fragments, (S)-3-(4-hydroxyphenyl) hex-4-ynoic acid (1) and 3-

SPIRO COMPOUNDS AND PHARMACEUTICAL USE THEREOF

The Spiro compound represented by the following general formula [Ia], its pharmaceutically acceptable salt or a solvate thereof

Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders

The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables Q, L1, L2, M, X, L3, and A are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.

Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders

The present invention provides compounds useful, for example, for modulating insulin levels in a subject and that have the general formula [in-line-formulae]Q-L1-P-L2-M-X-L3-A [/in-line-formulae] wherein the definitions of

Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders

The present invention provides compounds useful, for example, for modulating insulin levels in a subject, having the general formula I: wherein Q is an optionally substituted phenyl; L is a bond or O; P is a benzene or an optionally substituted thiazole r